Clinical Trial Search

Primary: Percentage of Participants With Anti-Meningococcal Serogroup C (Anti-MCC) Antibody (Ab) Titre ≥1:8 Dil One Month After MCC-TT or MCC-CRM (Part 1) — 100.0; 99.1…

Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants

Primary: Number of Participants Exclusively Breastfeeding at 3 Months, or 3 Months Corrected if the Infant Was Born Prematurely — 22; 24 Participants — p=0.40

Primary: Mean Change in Product of BSA (Body Surface Affected by Psoriasis) and sPGA (Static Physician Global Assessment) From Baseline to Week 16 — -9 score on a scale

Primary: Change From Baseline in Patient-Rated Low Back Pain (LBP), an 11 Point Numerical Rating Scale (NRS) — 1.8; 3.0; 2.3; 2.1 units on a scale

Primary: Fugl Meyer Assessment — 6.90; 4.00; 6.25; 10.10 units on a scale

Primary: Number of Participants With at Least One Dose Limiting Toxicity — 0; 0; 1 participants with DLTs

Primary: Change From Baseline to Week 8 in Mean Daily Average Pain Score as Assessed by Numerical Rating Scale (NRS) — -1.42; -1.36 Units on a scale — p=0.590

Primary: Number of Participants Free From Recurrent, Symptomatic Paroxysmal Atrial Fibrillation (PAF), Atrial Flutter (AFL), and Atrial Tachycardia (AT) — 111 Participants…

Primary: Percentage Change From Baseline in Serum TTR at Month 6 — -72.0 percentage change from baseline in TTR

Primary: Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT) — 4; 12 Participants

Primary: Number of Participants With PrEP Adherence — 45 Participants

Primary: Pain Management Used During Newborn Screening Blood Test — 30; 33 Participants

Primary: Number of Participants With Grade 3 and 4 Adverse Events — 12 Participants

Primary: Change From Baseline to Week 5 in the Montgomery Asberg Depression Rating Scale (MADRS) Total Score — -11.1; -8.4; -13.0; -2.2 units on a scale — p=0.109